Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Inversago"


2 mentions found


CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.
Persons: Jared Holz, ” Holz, , Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, , ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo
Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company's blockbuster weight loss portfolio. The deal's price depends on whether Inversago reaches certain development and sales goals, Novo Nordisk said in a release. Canada-based Inversago develops experimental therapies to treat people with obesity, diabetes and other conditions affecting the body's metabolism. Meanwhile, Novo Nordisk's Wegovy and Ozempic work by mimicking a hormone produced in the gut to suppress a person's appetite. Novo Nordisk intends to further investigate the potential of the oral drug for obesity and obesity-related complications.
Persons: Novo, Martin Holst Lange, Lars Fruergaard Jorgensen, availabilities Organizations: Novo Nordisk, Inversago Pharma, Novo, Novo Nordisk's Wegovy, Nordisk, Reuters Locations: Danish, Inversago, Canada, U.S
Total: 2